25+ years in Life Sciences, taking companies from inception to high value. Founded, built and sold Equazen Ltd (to Galenica) and Equateq Ltd (to BASF). CEO of NASDAQ-listed Avita Medical plc (regenerative medicine). PE/VC adviser
Prev: Equazen Ltd · Equateq Ltd · Avita Medical plc
Henry Chamberlain
CFO
LH
Lee Harle
Co-Founder
Why now
The rising global health epidemic of obesity and the emerging role of inflammation as a hidden driver of morbidity create a pressing need for effective solutions. The market is shifting towards natural and plant-based ingredients, with a significant portion of consumers preferring these options for healthcare products.
Problem
Obesity continues to rise as a global health epidemic, setting off a chain reaction of chronic conditions such as diabetes, liver disease, and certain cancers. Inflammation is emerging as a hidden driver of morbidity, escalating healthcare crises and contributing to the burden of chronic diseases.
Solution
Rejuvion Sciences is developing scientifically-backed plant extracts to address obesity and inflammation without the side effects of pharmaceutical alternatives. The company leverages ethnobotanical knowledge and scientific validation to create effective nutraceuticals.
Supports satiety with plant extracts underpinned by ethnobotanical knowledge from Kew Gardens
Reduces blood glucose, insulin requirements, and glycemic index through clinically supported ingredients
Uses Capsimax and Innoslim to enhance fat metabolism and fat breakdown
Formulation inhibits pro-inflammatory mechanisms and supports anti-inflammatory activity
Market
Where the opportunity sits.
TAM$500B
Growing at 30%
Tailwinds
78% global consumers prefer natural and plant-based ingredients in healthcare productsHigh exponential rise of world’s herbal medicine market
By geography
Global
$500B
"BRNDS market size of $126B."
Traction
The numbers.
$18.7M
Revenue
74%
Gross Profit Margin
$1.4T
Annual economic cost of obesity
$47T
Estimated cost of chronic diseases globally
174,000
US adults starting GLP-1 therapy
4.2M
GLP-1 prescriptions in EU
Business
Target segments
Broader market(20–70 years old, unisex)
Primarily older adults(40–70 years old, interested in longevity, inflammaging, chronic disease management)
Roadmap
Milestones funded by this round
D2C launch of Satimax and Inflamesse products in Q4 ’25
Scale in the UK and US market entry
Competition
Where we sit.
Positioning
Us Competitors
High
·
Depth of capability
Low
Low
Customer outcome
·
High
Us · Rejuvion Sciences
VITABIOTICS
GNUTRILITE
HERBALIFE
Category leader
Sub-cat
Val / rev
Yr
BRNDS
$126B
VITABIOTICS
$44B
GNUTRILITE
$26B
Direct
Their angle
Our edge
VITABIOTICS
Market size of $44B, known for consumer-centric approach and institutional credibility.
GNUTRILITE
Market size of $26B, focuses on scientific excellence and market advantages.
HERBALIFE
The ask
Raising
£1M
What this funds
· D2C launch of Satimax and Inflamesse products in Q4 ’25
· Scale in the UK and US market entry
Development£30k for development
Website & Digital Assets£35k to establish a strong digital and visual presence
Product Development£25k to finalise product development
Key Talent£50k to order product inventory and validate propositions
Regulatory & Compliance
Calibration — recent comparables
Company
Year
Multiple
Deal
Source
The Good Bug
2025
Fullife Healthcare
2026
Regulatory
Licensed, certified, compliant.
Licences
EU Food Supplements Directive 2002/46/EC — Establishes harmonized lists of vitamins and minerals permitted in food supplements, along with specific labeling requirements (such as recommended daily doses and warnings not to exceed them).
Data room
Request access to these files.
The financial model, cap table, references and the rest of the diligence pack — granted by the founder, one click for signed-in investors.
The deck
Watch it the way they pitched it.
The pitch deck
Tell us who's looking
Enter your name and email to open the deck — just so the founder knows who read it.
We share your details only with this founder, so they know you read their deck. No spam. The deck opens view-only.
Counsel
Advisors in our corner.
PM
Prof Monique Simmonds OBE
Co-Founder · Deputy Director of Science at Kew Gardens
30 years' experience of research into different aspects of plant and fungal chemistry with an emphasis on the economic value of natural products
PC
Prof Clare Bryant FBPhS
Professor of Innate Immunity at University of Cambridge
A Fellow of the American Academy of Microbiology. Expertise in inflammation, infection and anti-inflammatory pharmacology
GY
Giles Yeo
Professor of Molecular Neuroendocrinology at the University of Cambridge
Programme leader at the MRC Metabolic Diseases Unit. Expertise in genetics of obesity, appetite regulation, and science communication
Verified
Certifications & compliance.
EU Food Supplements Directive 2002/46/EC — Establishes harmonized lists of vitamins and minerals permitted in food supplements, along with specific labeling requirements (such as recommended daily doses and warnings not to exceed them).
Verbatim
In their own words.
Rejuvion Sciences is a cutting-edge nutraceutical company developing scientifically-backed plant extracts to address the twin global crises of obesity and inflammation without the side effects and limitations of pharmaceutical alternatives. executive summary
Formulations underway for initial launch in UK, followed by the US and Western European expansion. current status
Our innovation is fuelled by our academic alliances and unmatched scientific resources. scientific foundation
A solution targeting satiety, fat metabolism, and glucose regulation. product pipeline
Prof Monique Simmonds OBE, Deputy Director of Science at Kew Gardens; 30 years' experience of research into different aspects of plant and fungal chemistry. advisory board
Prof Clare Bryant FBPhS, Professor of Innate Immunity at University of Cambridge. advisory board
